Literature DB >> 17537851

Distinct gene expression profiling after infection of immature human monocyte-derived dendritic cells by the attenuated poxvirus vectors MVA and NYVAC.

Susana Guerra1, José Luis Nájera, José Manuel González, Luis A López-Fernández, Nuria Climent, José M Gatell, Teresa Gallart, Mariano Esteban.   

Abstract

Although recombinants based on the attenuated poxvirus vectors MVA and NYVAC are currently in clinical trials, the nature of the genes triggered by these vectors in antigen-presenting cells is poorly characterized. Using microarray technology and various analysis conditions, we compared specific changes in gene expression profiling following MVA and NYVAC infection of immature human monocyte-derived dendritic cells (MDDC). Microarray analysis was performed at 6 h postinfection, since these viruses induced extensive cytopathic effects, rRNA breakdown, and apoptosis at late times postinfection. MVA- and NYVAC-infected MDDC shared upregulation of 195 genes compared to uninfected cells: MVA specifically upregulated 359 genes, and NYVAC upregulated 165 genes. Microarray comparison of NYVAC and MVA infection revealed 544 genes with distinct expression patterns after poxvirus infection and 283 genes specifically upregulated after MVA infection. Both vectors upregulated genes for cytokines, cytokine receptors, chemokines, chemokine receptors, and molecules involved in antigen uptake and processing, including major histocompatibility complex genes. mRNA levels for interleukin 12beta (IL-12beta), beta interferon, and tumor necrosis factor alpha were higher after MVA infection than after NYVAC infection. The expression profiles of transcription factors such as NF-kappaB/Rel and STAT were regulated similarly by both viruses; in contrast, OASL, MDA5, and IRIG-I expression increased only during MVA infection. Type I interferon, IL-6, and Toll-like receptor pathways were specifically induced after MVA infection. Following MVA or NYVAC infection in MDDC, we found similarities as well as differences between these virus strains in the expression of cellular genes with immunological function, which should have an impact when these vectors are used as recombinant vaccines.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17537851      PMCID: PMC1951336          DOI: 10.1128/JVI.00444-07

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  82 in total

Review 1.  Synergistic DNA-MVA prime-boost vaccination regimes for malaria and tuberculosis.

Authors:  Sarah C Gilbert; Vasee S Moorthy; Laura Andrews; Ansar A Pathan; Samuel J McConkey; Jenni M Vuola; Sheila M Keating; Tamara Berthoud; Daniel Webster; Helen McShane; Adrian V S Hill
Journal:  Vaccine       Date:  2005-08-24       Impact factor: 3.641

2.  Cellular and biochemical differences between two attenuated poxvirus vaccine candidates (MVA and NYVAC) and role of the C7L gene.

Authors:  José Luis Nájera; Carmen Elena Gómez; Elena Domingo-Gil; María Magdalena Gherardi; Mariano Esteban
Journal:  J Virol       Date:  2006-06       Impact factor: 5.103

3.  Suppression of proinflammatory signal transduction and gene expression by the dual nucleic acid binding domains of the vaccinia virus E3L proteins.

Authors:  Jeffrey O Langland; John C Kash; Victoria Carter; Matthew J Thomas; Michael G Katze; Bertram L Jacobs
Journal:  J Virol       Date:  2006-10       Impact factor: 5.103

4.  Generation and immunogenicity of novel HIV/AIDS vaccine candidates targeting HIV-1 Env/Gag-Pol-Nef antigens of clade C.

Authors:  Carmen Elena Gómez; Jose Luis Nájera; Victoria Jiménez; Kurt Bieler; Jens Wild; Linda Kostic; Shirin Heidari; Margaret Chen; Marie-Joelle Frachette; Giuseppe Pantaleo; Hans Wolf; Peter Liljeström; Ralf Wagner; Mariano Esteban
Journal:  Vaccine       Date:  2006-12-06       Impact factor: 3.641

5.  Retinoic acid inducible gene-I and mda-5 are involved in influenza A virus-induced expression of antiviral cytokines.

Authors:  Jukka Sirén; Tadaatsu Imaizumi; Devanand Sarkar; Taija Pietilä; Diana L Noah; Rongtuan Lin; John Hiscott; Robert M Krug; Paul B Fisher; Ilkka Julkunen; Sampsa Matikainen
Journal:  Microbes Infect       Date:  2006-05-22       Impact factor: 2.700

6.  Differences and similarities in viral life cycle progression and host cell physiology after infection of human dendritic cells with modified vaccinia virus Ankara and vaccinia virus.

Authors:  Ann Chahroudi; David A Garber; Patrick Reeves; Luzheng Liu; Daniel Kalman; Mark B Feinberg
Journal:  J Virol       Date:  2006-09       Impact factor: 5.103

7.  Infection of human dendritic cells with recombinant vaccinia virus MVA reveals general persistence of viral early transcription but distinct maturation-dependent cytopathogenicity.

Authors:  Wolfgang Kastenmuller; Ingo Drexler; Holger Ludwig; Volker Erfle; Christian Peschel; Helga Bernhard; Gerd Sutter
Journal:  Virology       Date:  2006-04-03       Impact factor: 3.616

8.  Vaccinia virus infection attenuates innate immune responses and antigen presentation by epidermal dendritic cells.

Authors:  Liang Deng; Peihong Dai; Wanhong Ding; Richard D Granstein; Stewart Shuman
Journal:  J Virol       Date:  2006-10       Impact factor: 5.103

9.  Vaccination of colorectal cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax) induces immune responses which correlate with disease control: a phase I/II trial.

Authors:  Richard Harrop; Noel Connolly; Irina Redchenko; Juan Valle; Mark Saunders; Matthew G Ryan; Kevin A Myers; Noel Drury; Susan M Kingsman; Robert E Hawkins; Miles W Carroll
Journal:  Clin Cancer Res       Date:  2006-06-01       Impact factor: 12.531

10.  Human gene profiling in response to the active protein kinase, interferon-induced serine/threonine protein kinase (PKR), in infected cells. Involvement of the transcription factor ATF-3 IN PKR-induced apoptosis.

Authors:  Susana Guerra; Luis A López-Fernández; María Angel García; Angel Zaballos; Mariano Esteban
Journal:  J Biol Chem       Date:  2006-04-13       Impact factor: 5.157

View more
  57 in total

1.  Selective induction of host genes by MVA-B, a candidate vaccine against HIV/AIDS.

Authors:  Susana Guerra; José Manuel González; Núria Climent; Hugh Reyburn; Luis A López-Fernández; José L Nájera; Carmen E Gómez; Felipe García; José M Gatell; Teresa Gallart; Mariano Esteban
Journal:  J Virol       Date:  2010-06-09       Impact factor: 5.103

2.  Optimizing high dimensional gene expression studies for immune response following smallpox vaccination using Taqman® low density immune arrays.

Authors:  Ann L Oberg; Neelam Dhiman; Diane E Grill; Jenna E Ryan; Richard B Kennedy; Gregory A Poland
Journal:  J Immunol Methods       Date:  2011-01-28       Impact factor: 2.303

3.  Infection of nonhost species dendritic cells in vitro with an attenuated myxoma virus induces gene expression that predicts its efficacy as a vaccine vector.

Authors:  S Top; E Foulon; B Pignolet; M Deplanche; C Caubet; C Tasca; S Bertagnoli; G Meyer; G Foucras
Journal:  J Virol       Date:  2011-08-10       Impact factor: 5.103

4.  Role of cell signaling in poxvirus-mediated foreign gene expression in mammalian cells.

Authors:  Ningjie Hu; Richard Yu; Cecilia Shikuma; Bruce Shiramizu; Mario A Ostrwoski; Qigui Yu
Journal:  Vaccine       Date:  2009-03-10       Impact factor: 3.641

Review 5.  Candidate genes expressed in human islets and their role in the pathogenesis of type 1 diabetes.

Authors:  Joachim Storling; Caroline Anna Brorsson
Journal:  Curr Diab Rep       Date:  2013-10       Impact factor: 4.810

6.  The canarypox virus vector ALVAC induces distinct cytokine responses compared to the vaccinia virus-based vectors MVA and NYVAC in rhesus monkeys.

Authors:  Jeffrey E Teigler; Sanjay Phogat; Genoveffa Franchini; Vanessa M Hirsch; Nelson L Michael; Dan H Barouch
Journal:  J Virol       Date:  2013-11-20       Impact factor: 5.103

Review 7.  Vaccinia virus vaccines: past, present and future.

Authors:  Bertram L Jacobs; Jeffrey O Langland; Karen V Kibler; Karen L Denzler; Stacy D White; Susan A Holechek; Shukmei Wong; Trung Huynh; Carole R Baskin
Journal:  Antiviral Res       Date:  2009-06-26       Impact factor: 5.970

8.  Antibodies to gp120 and PD-1 expression on virus-specific CD8+ T cells in protection from simian AIDS.

Authors:  Monica Vaccari; Rabih Halwani; L Jean Patterson; Adriano Boasso; Jennifer Beal; Elzbieta Tryniszewska; Anna Hryniewicz; David Venzon; Elias K Haddad; Mohamed El-Far; Margherita Rosati; George N Pavlakis; Barbara K Felber; Saleh Al-Muhsen; Marjorie Robert-Guroff; Rafick-Pierre Sekaly; Genoveffa Franchini
Journal:  J Virol       Date:  2013-01-16       Impact factor: 5.103

9.  Suppression of NYVAC Infection in HeLa Cells Requires RNase L but Is Independent of Protein Kinase R Activity.

Authors:  Mercedes Fernández-Escobar; José Luis Nájera; Sara Baldanta; Dolores Rodriguez; Michael Way; Mariano Esteban; Susana Guerra
Journal:  J Virol       Date:  2015-12-09       Impact factor: 5.103

10.  Vaccinia virus infection & temporal analysis of virus gene expression: Part 2.

Authors:  Judy Yen; Ron Golan; Kathleen Rubins
Journal:  J Vis Exp       Date:  2009-04-10       Impact factor: 1.355

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.